Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pyrotinib + Trastuzumab rezetecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pyrotinib | SHR-1258|SHR1258 | EGFR Inhibitor (Pan) 63 HER2 Inhibitor 44 | Pyrotinib is an irreversible dual inhibitor of EGFR and ERBB2 (HER2), which potentially leads to decreased growth of EGFR and/or HER2-positive tumor cells (PMID: 28115222, PMID: 30596880). | |
| Trastuzumab rezetecan | SHR A1811|SHRA1811|SHR-A1811 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 | Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to the camptothecin derivative rezetecan, which potentially induces DNA damage and apoptosis in ERBB2 (HER2)-expressing tumor cells and inhibits tumor growth (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): LB031). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|